Patrick Horn, MD
Psychiatry · Oklahoma City, OKNPI 1841450855
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 619 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,045 and has fallen 82.1% since, to $366 in 2025. Among psychiatry clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 619 payments — averaging $13.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$963
- Otsuka America Pharmaceutical, Inc.$844
- Vanda Pharmaceuticals Inc.$816
- Indivior Inc.$797
- plus $3K from 11 others
What the payments were for
- Food & beverage$7,80495%
- Education$4115%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 96 | $1,166 |
| Alkermes, Inc. | 49 | $1,005 |
| Teva Pharmaceuticals USA, Inc. | 60 | $963 |
| Otsuka America Pharmaceutical, Inc. | 78 | $844 |
| Vanda Pharmaceuticals Inc. | 47 | $816 |
| Indivior Inc. | 42 | $797 |
| Sunovion Pharmaceuticals Inc. | 102 | $797 |
| AbbVie(2 entities) | 63 | $569 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $467 |
| Lundbeck LLC | 22 | $311 |
| Neurocrine Biosciences, Inc. | 16 | $225 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $104 |
| E.r. Squibb & Sons, L.L.C. | 3 | $55 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Neuronetics, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$424
- LATUDA$115
- SUBLOCADE$115
- ARISTADA INITIO$106
- REXULTI$106
How this compares
$8,215 in reported general payments places this provider in the 90th percentile of 328 psychiatry providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 35 | $316,878 |
| Invega SustennaPaliperidone Palmitate | 70 | $220,293 |
| AustedoDeutetrabenazine | 31 | $183,333 |
| IngrezzaValbenazine Tosylate | 15 | $125,460 |
| PerserisRisperidone | 33 | $96,959 |
| VraylarCariprazine Hcl | 50 | $78,525 |
| AristadaAripiprazole Lauroxil | 16 | $50,224 |
| RexultiBrexpiprazole | 22 | $45,016 |
| FanaptIloperidone | 11 | $38,973 |
| TrintellixVortioxetine Hydrobromide | 48 | $25,228 |
| Lurasidone Hcl | 165 | $23,933 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $19,022 |
| Quetiapine Fumarate | 613 | $12,037 |
| Aripiprazole | 230 | $9,057 |
| Doxepin Hcl | 204 | $6,984 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Invega | $1,166 | $544,093125 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $963 | $183,33331 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $225 | $125,46015 claims |
| Indivior Inc.Perseris | $797 | $96,95933 claims |
| AbbVieVraylar | $569 | $78,52550 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,005 | $69,24627 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $844 | $45,01622 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $816 | $38,97311 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $104 | $25,22848 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Oklahoma City
- Willis HollowayOklahoma City$92K
- Adonis Al BotrosOklahoma City$73K
- Marvin PeytonOklahoma City$60K
- Josephine DeguzmanOklahoma City$38K
- Haisam Al KhouriOklahoma City$10K
- Shreekuma VinekarOklahoma City$7K
- Relindis TitaOklahoma City$6K
- Janita ArdisOklahoma City$6K
- Fiona LiOklahoma City$5K
- Ahsan KhanOklahoma City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.